ライフサイエンスコーパス: cryptosporidiosis

1 for the development of drugs for malaria and cryptosporidiosis.

2 redominant allele associated with waterborne cryptosporidiosis.

3 or the treatment of symptoms associated with cryptosporidiosis.

4 typing to identify risk factors for sporadic cryptosporidiosis.

5 assessment of the role of raw vegetables in cryptosporidiosis.

6 erface in an in vitro model of human biliary cryptosporidiosis.

7 samples from the 1993 Milwaukee outbreak of cryptosporidiosis.

8 are efficacious in a chronic mouse model of cryptosporidiosis.

9 SP mRNA was associated with symptoms in cryptosporidiosis.

10 cular tool in epidemiologic studies of human cryptosporidiosis.

11 red to be the pathogen responsible for human cryptosporidiosis.

12 a are not key mediators of diarrhea in human cryptosporidiosis.

13 tes are crucial steps in the pathogenesis of cryptosporidiosis.

14 cific preventive or therapeutic measures for cryptosporidiosis.

15 provide optimal passive immunization against cryptosporidiosis.

16 t for passive or active immunization against cryptosporidiosis.

17 the importance of copathogens in symptomatic cryptosporidiosis.

18 pecies play protective roles in experimental cryptosporidiosis.

19 s are currently available for the control of cryptosporidiosis.

20 ith paromomycin and azithromycin for chronic cryptosporidiosis.

21 ould be studied as a potential treatment for cryptosporidiosis.

22 f 43 age-matched controls with no history of cryptosporidiosis.

23 olangitis seen in AIDS patients with biliary cryptosporidiosis.

24 ild growth in the community than symptomatic cryptosporidiosis.

25 s associated with delayed time to subsequent cryptosporidiosis.

26 , is an exciting drug candidate for treating cryptosporidiosis.

27 t for passive or active immunization against cryptosporidiosis.

28 ited to develop an in vitro model of biliary cryptosporidiosis.

29 ulations within ileal mucosae of calves with cryptosporidiosis.

30 ion was characterized with a bovine model of cryptosporidiosis.

31 mportant for resistance to and resolution of cryptosporidiosis.

32 nd response to therapeutic agents in biliary cryptosporidiosis.

33 actors, modes of transmission, and impact of cryptosporidiosis.

34 seases including malaria, toxoplasmosis, and cryptosporidiosis.

35 arameters and efficacy in the mouse model of cryptosporidiosis.

36 es and the identification of a drug to treat cryptosporidiosis.

37 the treatment of life-threatening paediatric cryptosporidiosis.

38 ndritic cell (cDC1)-deficient mice developed cryptosporidiosis.

39 ted with increased risk for life-threatening cryptosporidiosis.

40 matched individuals living with HIV without cryptosporidiosis.

41 on of a new effective and safe treatment for cryptosporidiosis.

42 ction remains an important goal for tackling cryptosporidiosis.

43 a having a modest, but measurable, effect on cryptosporidiosis.

44 logy and the development of vaccines against cryptosporidiosis.

45 with human immunodeficiency virus (HIV) with cryptosporidiosis.

46 sing on malaria, kinetoplastid diseases, and cryptosporidiosis.

47 ion as a drug candidate for the treatment of cryptosporidiosis.

48 cause, including toxoplasmosis, malaria, and cryptosporidiosis.

49 for effective management of human and animal cryptosporidiosis.

50 er IS reduction nor specific therapy against cryptosporidiosis.

51 ction, and in a neonatal dairy calf model of cryptosporidiosis.

52 as a lead compound for drug development for cryptosporidiosis.

53 al efficacy evaluation in the calf model for cryptosporidiosis.

54 utic drug leads in an animal model for human cryptosporidiosis.

55 or the development of drugs for treatment of cryptosporidiosis.

56 m parasites infect intestinal cells, causing cryptosporidiosis.

57 isease burden was also seen in children with cryptosporidiosis.

58 diseases such as malaria, toxoplasmosis, and cryptosporidiosis.

59 seases including malaria, toxoplasmosis, and cryptosporidiosis.

60 sative agents of malaria, toxoplasmosis, and cryptosporidiosis.

61 gs may be an effective strategy for treating cryptosporidiosis.

62 ility of HIV-infected individuals to biliary cryptosporidiosis.

63 serve as potential therapeutics for treating cryptosporidiosis.

64 n ideal model for enteric infections such as cryptosporidiosis.

65 cation in interventional in vitro studies of cryptosporidiosis.

66 val among AIDS patients with newly diagnosed cryptosporidiosis?

67 mal volunteers (median in AIDS patients with cryptosporidiosis, 508 pg/mg protein, compared to 111 pg

68 There is no vaccine to protect from cryptosporidiosis, a leading cause of diarrhea in infant

69 ated its expression and role during neonatal cryptosporidiosis, a worldwide protozoan enteric disease

70 er was not associated with a reduced risk of cryptosporidiosis (adjusted RR = 0.86; 95% CI, .60-1.23)

71 in the number of HIV-infected patients with cryptosporidiosis after the period of water contaminatio

72 This study documented a high burden of cryptosporidiosis among children in an endemic Indian sl

73 A total of 194 cases of cryptosporidiosis among HIV-infected patients were ident

74 To assess the risk factors for sporadic cryptosporidiosis among immunocompetent persons, a match

75 Cryptosporidiosis, an enteric protozoon, causes substant

76 lving 282 persons with laboratory-identified cryptosporidiosis and 490 age-matched and geographically

77 (HIV)-positive patients newly diagnosed with cryptosporidiosis and all 3,564 patients with newly diag

78 with protection of Bangladeshi infants from cryptosporidiosis and amebiasis.

79 rable with appropriate antimicrobial agents; cryptosporidiosis and C. difficile infections may howeve

80 Cryptosporidiosis and giardiasis are major public health

81 s with AIDS with naturally occurring chronic cryptosporidiosis and healthy volunteers with mild crypt

82 nd 72 pg/mg protein in AIDS patients without cryptosporidiosis and in normal volunteers, respectively

83 uggesting that cross-species transmission of cryptosporidiosis and microsporidiosis is possible.

84 asis, and some new leads on the treatment of cryptosporidiosis and refractory giardiasis.

85 unsupplemented animals developed persistent cryptosporidiosis and shed high levels of oocysts in the

86 y widely used drugs fail in the treatment of cryptosporidiosis and suggest more promising targets.

87 Understanding the natural history of cryptosporidiosis and the correlates of protection are e

88 in the understanding of the pathogenesis of cryptosporidiosis and the diagnosis of amebiasis and gia

89 ighlights the importance of surveillance for cryptosporidiosis and the need for guidelines for the pr

90 The search for effective therapeutics for cryptosporidiosis and toxoplasmosis has led to the disco

91 cause important diseases including malaria, cryptosporidiosis and toxoplasmosis.

92 important human diseases including malaria, cryptosporidiosis and toxoplasmosis.

93 culosis, chronic herpes simplex, and chronic cryptosporidiosis) and an increase occurred in recurrent

94 Patients with AIDS, chronic cryptosporidiosis, and < 100 CD4 cells/microL were treat

95 tions caused by enteric protozoa (amebiasis, cryptosporidiosis, and giardiasis), rotavirus, astroviru

96 tunistic infections (malaria, toxoplasmosis, cryptosporidiosis, and Pneumocystis carinii pneumonia).

97 ry diagnosis is required to confirm cases of cryptosporidiosis, and species and genotype determinatio

98 onsible for global scourges such as malaria, cryptosporidiosis, and toxoplasmosis.

99 is a consistent feature of human and animal cryptosporidiosis, and yet their contribution to the pat

100 in was shown to be ineffective treatment for cryptosporidiosis; and these parasitic diseases continue

101 Most human cases of cryptosporidiosis are associated with C. hominis and C.

102 r mechanisms involved in the pathogenesis of cryptosporidiosis are unknown.

103 lestones include: (i) recognition in 1980 of cryptosporidiosis as an acute enteric disease; (ii) its

104 Cryptosporidiosis as an initial AIDS-defining diagnosis

105 f the microbiota associated with severity of cryptosporidiosis, as determined by estimating oocyst ou

106 PK1) are leading candidates for treatment of cryptosporidiosis-associated diarrhea.

107 Differences in the incidence of cryptosporidiosis between bottled and municipal water gr

108 the first report of possible transmission of cryptosporidiosis between humans and dogs.

109 vidity that is associated with a decrease in cryptosporidiosis but not in subclinical Cryptosporidium

110 with effective therapy in the mouse model of cryptosporidiosis, but a more refined model for efficacy

111 or immunotherapies have been identified for cryptosporidiosis, but certain antibodies directed again

112 arded weight gain more than did asymptomatic cryptosporidiosis, but the latter was twice as common.

113 testinal fluid secretion in animal models of cryptosporidiosis, but their cellular sources and mechan

114 ren completing follow-up, 397 (97%) acquired cryptosporidiosis by 3 years of age.

115 plays an important role in the resolution of cryptosporidiosis by attracting immune effector cells to

116 tein malnutrition may enhance (or intensify) cryptosporidiosis by suppressing C. parvum-induced cell

117 ldren with a symptomatic diarrhea episode of cryptosporidiosis (case-children) were compared with tho

118 ch Transplantation Society, we collected all cryptosporidiosis cases identified in solid organ transp

119 In 2012, cryptosporidiosis cases increased in the Netherlands, bu

120 utbreaks account for only 10% of the overall cryptosporidiosis cases, and there are few data on the s

121 Malaria and cryptosporidiosis, caused by apicomplexan parasites, rem

122 Cryptosporidiosis, caused by Cryptosporidium parvum, is

123 Cryptosporidiosis, caused by the apicomplexan parasite C

124 Cryptosporidiosis, caused by the apicomplexan parasite C

125 the identification of a novel treatment for cryptosporidiosis, caused by the parasite Cryptosporidiu

126 Cryptosporidiosis, caused by the protozoan parasite Cryp

127 nts had additional immunodepression favoring cryptosporidiosis (CD40 ligand deficiency [n = 1], human

128 diseases, including malaria, toxoplasmosis, cryptosporidiosis, coccidiosis and babesiosis.

129 ignificantly increased in AIDS patients with cryptosporidiosis compared to the level in AIDS patients

130 Cryptosporidiosis continues to challenge old and new che

131 pothesized that passive immunization against cryptosporidiosis could be improved by using neutralizin

132 oplasma gondii), leishmaniasis (Leishmania), cryptosporidiosis (Cryptosporidium), and trypanosomiasis

133 Diarrhea attributed to Cryptosporidium (cryptosporidiosis) decreased from a peak of 0.19 episode

134 e human immunodeficiency virus (HIV) in whom cryptosporidiosis developed during the outbreak.

135 ns: 1) How do AIDS patients who present with cryptosporidiosis differ from other patients with AIDS?

136 Cryptosporidiosis drug and vaccine development is limite

137 In neonatal calves, a clinical model of cryptosporidiosis, EDI048 treatment resulted in rapid re

138 We established an in vitro model of biliary cryptosporidiosis employing a human biliary epithelial c

139 as epidemiologic tools for the detection of cryptosporidiosis episodes in children from a Peruvian c

140 No reliable therapy for cryptosporidiosis exists, though the aminoglycoside paro

141 Severity of cryptosporidiosis explained a smaller, though significan

142 intraepithelial lymphocytes from calves with cryptosporidiosis expressed IFN-gamma but not TNF-alpha.

143 crobiota markers associated with severity of cryptosporidiosis, fecal microbiota from individually ca

144 Malnutrition and cryptosporidiosis form a vicious cycle and lead to acute

145 In biopsies from AIDS patients with active cryptosporidiosis, four chemokines (CXCL10, CCL11 [eotax

146 ladeshi children longitudinally followed for cryptosporidiosis from birth to 3 years of age allowed f

147 On average, children with symptomatic cryptosporidiosis gained (i.e., grew) 342 g less (95% co

148 Cryptosporidiosis, giardiasis and microsporidiosis are s

149 Cryptosporidiosis has been identified as one of the majo

150 The role of dogs and cats in human cryptosporidiosis has been the focus of much attention.

151 The only drug approved for cryptosporidiosis has limited efficacy in high-risk popu

152 However, its role in cryptosporidiosis has not been fully studied.

153 effective in treating people suffering from cryptosporidiosis has prompted the development of in viv

154 Although several animal models of cryptosporidiosis have been reported, most involve genet

155 the developing world, current therapies for cryptosporidiosis have limited efficacy.

156 t models for evaluating drug therapy against cryptosporidiosis have many limitations, including the n

157 65917 may potentially be used to treat human cryptosporidiosis; however, further investigations are r

158 well-established as a source in outbreaks of cryptosporidiosis; however, the role of tap water in end

159 e patients received specific therapy against cryptosporidiosis ie nitozoxanide, 25 in monotherapy, an

160 3) Does a diagnosis of cryptosporidiosis impact survival after AIDS diagnosis?

161 d microbiology records identified 3 cases of cryptosporidiosis in 1992 (the first year that cryptospo

162 dentified microsporidiosis in 7 patients and cryptosporidiosis in 2 patients.

163 infection-related complications, with severe cryptosporidiosis in 6.

164 ort the efficacy of CFZ for the treatment of cryptosporidiosis in a severely immunocompromised HIV po

165 istently effective antiparasitic therapy for cryptosporidiosis in AIDS.

166 Cryptosporidiosis in Bangladeshi children aged 2-5 year

167 yptosporidium canis is an important cause of cryptosporidiosis in canines and humans.

168 complexan parasites, the causative agents of cryptosporidiosis in humans and/or animals.

169 has been linked by several investigators to cryptosporidiosis in humans.

170 ere highly protective against development of cryptosporidiosis in immune-suppressed HIV-infected pers

171 ay be important in controlling the burden of cryptosporidiosis in immunosuppressed individuals.

172 infection in families we found high rates of cryptosporidiosis in infants and children, and prolonged

173 hin the home may be essential for preventing cryptosporidiosis in infants.

174 Thus, the transmission of cryptosporidiosis in Kuwaiti children differed significa

175 The increased risk of cryptosporidiosis in MBL deficiency appears to include p

176 ts of MBL deficiency appear to predispose to cryptosporidiosis in patients with the acquired immunode

177 Cryptosporidiosis in rural sub-Saharan Africa is charact

178 There is a high burden of endemic cryptosporidiosis in southern India.

179 ol study examining risk factors for sporadic cryptosporidiosis in the Netherlands.

180 ess, but few studies have evaluated sporadic cryptosporidiosis in the United States.

181 es is often reported as the primary cause of cryptosporidiosis in this country.

182 s study we found that most sporadic cases of cryptosporidiosis in Wisconsin are caused by zoonotic Cr

183 s of Cryptosporidium in 49 cases of sporadic cryptosporidiosis in Wisconsin during the period from 20

184 New drugs for the treatment of malaria and cryptosporidiosis, in particular, are of high priority;

185 In Scotland, rates of cryptosporidiosis infection in humans peak during the sp

186 ring 2002, there was recovery in the rate of cryptosporidiosis infection in humans throughout Scotlan

187 as a significant reduction in human cases of cryptosporidiosis infection in southern Scotland, where

188 We associate the reduction in human cases of cryptosporidiosis infection with the reduction in the nu

189 Nitazoxanide (NTZ), originally used to treat cryptosporidiosis infection, recently was shown to have

190 Cryptosporidiosis is a common cause of diarrhea morbidit

191 Cryptosporidiosis is a diarrheal disease caused by infec

192 Cryptosporidiosis is a diarrheal disease caused by the p

193 Cryptosporidiosis is a late posttransplant infection tha

194 Cryptosporidiosis is a leading cause of diarrheal diseas

195 Cryptosporidiosis is a leading cause of life-threatening

196 Cryptosporidiosis is a leading cause of life-threatening

197 Cryptosporidiosis is a leading cause of waterborne diarr

198 Cryptosporidiosis is a major cause of diarrheal disease.

199 Cryptosporidiosis is a parasitic disease associated with

200 Cryptosporidiosis is a serious disease in malnourished c

201 Cryptosporidiosis is a significant cause of food-borne a

202 Cryptosporidiosis is a significant diarrhoeal disease in

203 Although the clinical severity of cryptosporidiosis is altered by human immunodeficiency v

204 Cryptosporidiosis is an emerging infectious disease that

205 Cryptosporidiosis is an important diarrheal disease of h

206 Biliary cryptosporidiosis is associated with acquired immunodefi

207 Cryptosporidiosis is caused by infection of the small in

208 Human cryptosporidiosis is caused primarily by two species of

209 Cryptosporidiosis is classically reported in patients wi

210 Cryptosporidiosis is increasingly identified as an impor

211 Since asymptomatic cryptosporidiosis is more prevalent, it may have more of

212 However, the current treatment for cryptosporidiosis is suboptimal.

213 Human cryptosporidiosis is the leading protozoan cause of diar

214 The GKO mouse model of cryptosporidiosis is useful for discerning isolate-speci

215 These infections include cryptosporidiosis, isosporiasis, and microsporidiosis.

216 lows: toxoplasmosis, 91% and 86 (5.24/0.06); cryptosporidiosis/isosporiasis, 90% and infinite (1.61/0

217 June 1994; at least 20 of the 32 (62.5%) had cryptosporidiosis listed on their death certificates.

218 A One Health approach to tackle zoonotic cryptosporidiosis looking at new advances in veterinary,

219 uggests that acquired protective immunity to cryptosporidiosis may be important in controlling the bu

220 A total of 186 episodes of cryptosporidiosis, mostly asymptomatic, were observed in

221 rgan transplant recipients (41 kidneys) with cryptosporidiosis, mostly men (68%), with a median age o

222 trates that malnourished children with acute cryptosporidiosis mount inflammatory, Th-2, and counterr

223 our lead compound shows oral efficacy in two cryptosporidiosis mouse models.

224 lunteers who developed signs and symptoms of cryptosporidiosis (n = 11) than among asymptomatic infec

225 Cryptosporidiosis occurred at a median time of 3.4 (0-19

226 In 1994, an outbreak of cryptosporidiosis occurred in a rural community in Washi

227 cryptosporidium and a widespread outbreak of cryptosporidiosis occurred.

228 ons who drank only bottled water to have had cryptosporidiosis (odds ratio, 4.22 [95% Cl, 1.22 to 14.

229 ral gene mutations were at increased risk of cryptosporidiosis (odds ratio, 8.2; 95% confidence inter

230 gest that treatment with IFN-gamma may limit cryptosporidiosis of the small intestine.

231 Fifty-eight (25.7%) had cryptosporidiosis, of whom 17 (29.3%) had recurrent dise

232 nanoparticles for the molecular diagnosis of cryptosporidiosis, offering new opportunities for the fu

233 nfection, as well as the community impact of cryptosporidiosis on this population.

234 sporidiosis and healthy volunteers with mild cryptosporidiosis or asymptomatic infection after experi

235 mpared to the level in AIDS patients without cryptosporidiosis or in normal volunteers (median in AID

236 In September and October 1998, a cryptosporidiosis outbreak occurred on a Washington, DC,

237 A cryptosporidiosis outbreak was associated with municipal

238 Most cryptosporidiosis outbreaks in the United States have be

239 nd 31 March 2014, concurrent shigellosis and cryptosporidiosis outbreaks occurred among men who have

240 ocyte count (P<.0001), no ART (P<.0001), and cryptosporidiosis (P=.004) but not with microsporidiosis

241 r ongoing public health education to prevent cryptosporidiosis, particularly among travelers, animal

242 ly recognized by serum antibodies from human cryptosporidiosis patients.

243 pecimens from asymptomatic subjects and from cryptosporidiosis patients.

244 Children with cryptosporidiosis presented early, and most had abdomina

245 abolites augment the host immune response to cryptosporidiosis, protecting against disease.

246 months was associated with a higher risk of cryptosporidiosis (rate ratio [RR] = 1.40; 95% confidenc

247 fic drugs, vaccines, and immunotherapies for cryptosporidiosis relates in part to limited knowledge o

248 rvival of AIDS patients with newly diagnosed cryptosporidiosis relative to patients with other AIDS-d

249 Thus, the pathogenesis of cryptosporidiosis remains poorly characterized, and inte

250 wimming pool outbreaks of cyclosporiasis and cryptosporidiosis, respectively, occurred in North Ameri

251 Symptomatic cryptosporidiosis retarded weight gain more than did asy

252 ions (malaria, leishmaniasis, toxoplasmosis, cryptosporidiosis, strongyloidiasis, and filariasis) as

253 sociation between drinking bottled water and cryptosporidiosis suggests possible spread from asymptom

254 tion in neonatal calves, a clinical model of cryptosporidiosis that closely resembles human infection

255 the role of the gut microbiota in diarrheal cryptosporidiosis, the microbiome composition of both di

256 6 and 15 are promising preclinical leads for cryptosporidiosis therapy with acceptable safety paramet

257 Similar to human cryptosporidiosis, this infection causes intestinal path

258 ing the interaction between malnutrition and cryptosporidiosis through immunostaining and immunoblott

259 This outbreak illustrates the potential for cryptosporidiosis to cause foodborne illness.

260 human and animal diseases, such as malaria, cryptosporidiosis, toxoplasmosis, and coccidiosis, and n

261 ssess the therapeutic potential of drugs for cryptosporidiosis treatment.

262 In vitro models of biliary cryptosporidiosis using a human biliary epithelial cell

263 ere noted in patients with AIDS with chronic cryptosporidiosis versus immunocompetent volunteers with

264 s reportedly taking clarithromycin developed cryptosporidiosis vs 30 of the 707 patients not taking c

265 the 214 patients taking rifabutin developed cryptosporidiosis vs 33 of the 805 not taking rifabutin

266 Cryptosporidiosis was complicated by renal failure in 15

267 s/mm3, the association between tap water and cryptosporidiosis was even stronger (odds ratio, 13.52 [

268 The effect of asymptomatic cryptosporidiosis was less severe: On average, children

269 Notably, the decrease in cryptosporidiosis was not accompanied by a decline in su

270 idium a century ago, and for almost 70 years cryptosporidiosis was regarded as an infrequent and insi

271 yptosporidiosis in 1992 (the first year that cryptosporidiosis was reportable in Nevada), 23 cases in

272 Using an in vitro model of human biliary cryptosporidiosis, we found that recombinant Tat protein

273 Using an in vitro model of human intestinal cryptosporidiosis, we report here that some of these C.

274 Plasma levels of CFZ in participants with cryptosporidiosis were 2-fold lower than in part B contr

275 ith both control groups, children with acute cryptosporidiosis were more malnourished (including meas

276 gressive multifocal leukoencephalopathy, and cryptosporidiosis were the least common disorders, with

277 is a leading cause of the diarrheal disease cryptosporidiosis, whose incidence in the United States

278 Treatment of cryptosporidiosis with azithromycin and paromomycin was

279 nhibitors could potentially be used to treat cryptosporidiosis with minimal effects on its mammalian

280 PCR identified 1053 episodes of cryptosporidiosis, with an overall incidence of 0.86 inf

281 e extent of person-to-person transmission of cryptosporidiosis within an urban and a rural community

282 families with infants to determine rates of cryptosporidiosis within households during the coronavir